Clinical Collaborations, Health Insurance, Pharmaceutical, Specialty Drug
Highmark’s Strategy to Contain Drug Costs Includes an Increasing Number of Outcome-Based Contracts
20
Aug
Aug
Pharmaceutical manufacturers and payers have developed a number of agreements under which reimbursement is contingent on specific outcomes over the last few years